Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1... by Ebers, G, Rice, G, Lesaux, J, Paty, D, Oger, J, Li, D, Beall, S, Devonshire, V, Hashimoto, S, Hooge, J, Kastrukoff, L, Krieger, C, Mezei, M, Seland, P, Vorobeychi, G, Morrison, W, Nelson, J, Freedman, MS, Chrisie, S, Nelson, R, Rabinovitch, H, Freedman, C, Hartung, H, Rieckmann, P, Archelos, J

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL by Duquette, P, Despault, L, Knobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Lapierre, Y, Greenstein, J, Mishra, B, Delillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B

Genetic susceptibility to MS: a second stage analysis in Canadian MS families. by Dyment, D, Willer, C, Scott, B, Armstrong, H, Ligers, A, Hillert, J, Paty, D, Hashimoto, S, Devonshire, V, Hooge, J, Kastrukoff, L, Oger, J, Metz, L, Warren, S, Hader, W, Power, C, Auty, A, Nath, A, Nelson, R, Freedman, M, Brunet, D, Paulseth, J, Rice, G, O'Connor, P, Duquette, P

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years by Duquette, P, Girard, M, Dubois, R, Kobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Greenstein, J, Mishra, B, DeLillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B